Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Moody's Corporation (MCO) Price & Performance

Amylx Pharmaceuticals IncTrade
Moody's CorporationTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Moody's Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.64B), while Moody's Corporation trades at $476.73 (market cap $82.52B). The key difference: Moody's Corporation is far larger — about 31.3× Amylx Pharmaceuticals Inc's market cap, and Moody's Corporation pays a 0.86% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMLXMCO
Market Cap
$2.64B$82.52B
Sector
HealthFinancials
52-Week High
$24.19$539.61
52-Week Low
$7.82$412.23
Enterprise Value
$2.39B$88.54B
Dividend Yield
0.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

Moody's Corporation

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Moody's Corporation

Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.

Read more on MCO